The cancer patients on floor K9 were among the sickest at Mission Hospital, in need of close monitoring. Dr. Martin Palmeri, ...
For patients across all indications treated within the RP2D range early, promising progression-free survival (PFS) and ...
Q3 2025 Earnings Call Transcript November 10, 2025 FibroGen, Inc. beats earnings expectations. Reported EPS is $-1.61, ...
The Scottish Medicines Consortium (SMC) announced today that they have accepted Kisqali (ribociclib) for use within NHS Scotland as an adjuvant treatment option in combination with an aromatase ...
Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data ...
Pancytopenia and thrombocytopenia, but not mortality, were elevated in patients with lupus receiving immune checkpoint ...
Pretreatment eosinophilia in NSCLC patients is associated with increased immune-related adverse events and reduced progression-free survival when treated with ICIs. The review included 11 ...